Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irbesartan for Retinal Endothelial Function in Hypercholesterolemia
NCT00152698Phase 3Withdrawn
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Nov 2009
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia comparing Irbesartan with Placebo (2 arms). Primary endpoint: Comparison of retinal endothelial function between hypercholesterolemic patients and healthy control subjects. Planned start Nov 2009; status: withdrawn.
02
Drugs
irbesartan
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT00152698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00152698.